Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 11, 2023 12:00 ET | Source: Quanta Therapeutics, Inc.

Quanta Therapeutics Presents Late-Breaking Data for QTX3034, a multi-KRAS inhibitor, at AACR-NCI-EORTC Conference

The combination of QTX3034, a multi-KRAS inhibitor, and EGFR inhibitors demonstrated potent, synergistic anti-tumor activity in preclinical studies.
May 22, 2023 09:00 ET | Source: Quanta Therapeutics, Inc.

Quanta Therapeutics Raises Over $50 Million in Series D Financing to Advance its Pipeline of KRAS Inhibitors

– Funds will support advancement of two KRAS inhibitor programs into the clinic in 2024 –– Financing led by Avidity Partners, with participation from syndicate of existing investors – RADNOR, Pa....
April 14, 2023 12:05 ET | Source: Quanta Therapeutics, Inc.

Quanta Therapeutics Presents Data from KRAS Inhibitor Pipeline at Annual AACR Meeting in Late-Breaking Research Session

- Data highlight favorable preclinical profiles for two chemically-distinct allosteric, oral small molecule KRAS inhibitors with potent anti-tumor activity - ORLANDO, Fla., April 14, 2023 (GLOBE...
March 14, 2023 16:35 ET | Source: Quanta Therapeutics, Inc.

Quanta Therapeutics Announces Two Late-Breaking Preclinical Presentations from KRAS Inhibitor Pipeline at Annual AACR Meeting

SOUTH SAN FRANCISCO, Calif., March 14, 2023 (GLOBE NEWSWIRE) -- Quanta Therapeutics, a privately-held biopharmaceutical company pioneering complex-directed therapies to treat RAS-driven cancers,...
December 13, 2022 08:55 ET | Source: Quanta Therapeutics, Inc.

Quanta Therapeutics Appoints Leonardo Faoro, MD, as Chief Medical Officer

– US board-certified medical oncologist with extensive global clinical and regulatory experience advancing oncology medicines from early development stages through to approval – – Quanta is...